ReviewFrontiers in microbiology2024
Genetic diversity, evolution and drug resistance of
Review in Frontiers in microbiology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed.
- Drug-resistance profiles, population structure, genomic clustering, and temporal trends in drug resistance amongThe Lancet regional health. Europe · 2026Article
- Can Diagnostic Delay Amplify Drug Resistance in Tuberculosis? A Critical Integrative Reflection on Bacterial Adaptation, Persistence, Within-Host Evolution, and Heteroresistance.Diseases (Basel, Switzerland) · 2026Article
- Transmission heterogeneity amongiScience · 2026Article
- Bedaquiline resistance-associated genetic mutations and minimum inhibitory concentrations in drug-resistant tuberculosis clinical isolates from Limpopo province, South Africa.Frontiers in microbiology · 2026Article
- Lineage-Dependent IFN-γ Responses to Drug-Sensitive and Isoniazid-ResistantInfection and drug resistance · 2026Article
- Genomic Surveillance of 3R Genes Associated with Antibiotic Resistance inAntibiotics (Basel, Switzerland) · 2025Article
- Spatiotemporal distribution ofEmerging microbes & infections · 2025Article
- Genomic characterization and epidemiology of Mycobacterium tuberculosis lineage 2 isolates from Kazakhstan.Scientific reports · 2025Article
- Reimagining Tuberculosis Control in the Era of Genomics: The Case for Global Investment inPathogens (Basel, Switzerland) · 2025Review
- Impact of sublineage diversity on intrinsic susceptibility of Beijing genotype Mycobacterium tuberculosis.Annals of clinical microbiology and antimicrobials · 2025Article
- Comprehensive Whole Genome Sequencing Dataset of Mycobacterium tuberculosis Strains Collected Across Italy.Scientific data · 2025Article
- Epidemiological Profile andInternational journal of microbiology · 2025Article
- Empowering tuberculosis genomic surveillance in Limpopo, South Africa through capacity building.Frontiers in public health · 2025Article
- [Tuberculosis: Analysis of the history and development of multiple antibiotic resistance].Revista medica del Instituto Mexicano del Seguro Social · 2024Review
- The chosen few:Frontiers in immunology · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.